Glenmark Pharmaceuticals Limited has informed the Exchange about Appointment of M/s. Rauthan & Associates LLP as the Secretarial Auditors of the Company.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals' board, meeting on August 14, 2025, approved transferring its Consumer Care business to a newly incorporated wholly owned subsidiary, Glenmark Consumer Care Limited, for about INR 240.40 Crores. The Consumer Care unit contributed INR 514.7 Crores in revenue (5.6% of standalone turnover) and INR 249.2 Crores in net worth (1.0% of total) in FY25, and the transfer is expected to complete by December 31, 2025. The board also appointed Ms. Patricia Andrews, a US-based pharma and biotech industry veteran, as an Additional Non-Executive Independent Director for a five-year term. Additionally, Walker Chandiok & Co. LLP was named Statutory Auditor and Rauthan & Associates LLP as Secretarial Auditor, both for five-year terms subject to shareholder approval. The 47th Annual General Meeting was scheduled for September 26, 2025, via video conferencing.
The Consumer Care business hive-off into a separate subsidiary aims to give the segment sharper strategic focus and operational flexibility, which could improve valuation visibility for both the pharma core and the consumer business. The new auditor and director appointments are routine governance matters and unlikely to move the stock on their own.